Free Account Opening + AMC Free Demat
Loading...

Glenmark Life Sciences IPO vs Tatva Chintan Pharma IPO

Comparision between Glenmark Life Sciences IPO and Tatva Chintan Pharma IPO.

IPO Details

Glenmark Life Sciences IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Tatva Chintan Pharma IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Glenmark Life Sciences IPO is up to ₹1,513.60 Cr whereas the issue size of the Tatva Chintan Pharma IPO is up to ₹500.00 Cr. The final issue price of Glenmark Life Sciences IPO is ₹720.00 per share and of Tatva Chintan Pharma IPO is ₹1,083.00 per share.

  Glenmark Life Sciences IPO Tatva Chintan Pharma IPO
Face Value ₹2 per share ₹10 per share
Issue Price (Lower) ₹695.00 per share ₹1,073.00 per share
Issue Price (Upper) ₹720.00 per share ₹1,083.00 per share
Issue Price (Final) ₹720.00 per share ₹1,083.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 20 shares 13 shares
Fresh Issue Size
Fresh Issue Size (Amount) up to ₹1,060.00 Cr up to ₹225.00 Cr
OFS Issue Size 63,00,000 shares
OFS Issue Size (Amount) up to ₹453.60 Cr up to ₹275.00 Cr
Issue Size Total
Issue Size Total (Amount) up to ₹1,513.60 Cr up to ₹500.00 Cr

IPO Timetable

Glenmark Life Sciences IPO opens on Jul 27, 2021, while Tatva Chintan Pharma IPO opens on Jul 16, 2021. The closing date of Glenmark Life Sciences IPO and Tatva Chintan Pharma IPO is Jul 29, 2021, and Jul 20, 2021, respectively.

  Glenmark Life Sciences IPO Tatva Chintan Pharma IPO
Anchor Bid Date
Issue Open Jul 27, 2021 Jul 16, 2021
Issue Close Jul 29, 2021 Jul 20, 2021
Basis Of Allotment (Tentative) Aug 03, 2021 Jul 26, 2021
Initiation of Refunds (Tentative) Aug 04, 2021 Jul 27, 2021
Credit of Share (Tentative) Aug 05, 2021 Jul 28, 2021
Listing date (Tentative) Aug 06, 2021 Jul 29, 2021
Anchor Lockin End date 1 Sep 02, 2021 Aug 25, 2021
Anchor Lockin End date 2 Nov 01, 2021 Oct 24, 2021

Financials

Glenmark Life Sciences IPO P/E ratio is , as compared to Tatva Chintan Pharma IPO P/E ratio of .

  Glenmark Life Sciences IPO Tatva Chintan Pharma IPO
Financial
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (₹ in million)
31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 19,970.75 17,256.04 14,753.95
Total Revenue 18,859.76 15,493.03 8,868.65
Profit After Tax 3,515.81 3,130.98 1,955.92
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (₹ in million)
31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 3,148.03 2,489.38 1,875.08
Total Revenue 3,062.92 2,646.22 2,068.01
Profit After Tax 522.62 377.89 205.43
Promoter Shareholding (Pre-Issue) 100% 100%
Promoter Shareholding (Post-Issue) 82.84% 79.17%
P/E Ratio
Market Cap
ROE
ROCE
Debt/Equity
EPS
RoNW

Shares Offered

In the Glenmark Life Sciences IPO retail investors (RII) are offered 75,43,130 shares while in Tatva Chintan Pharma IPO retail investors are offered 75,43,130 shares. Qualified institutional buyers (QIB) are offered 42,42,379 shares in Glenmark Life Sciences IPO and 9,31,966 shares in Tatva Chintan Pharma IPO.

  Glenmark Life Sciences IPO Tatva Chintan Pharma IPO
Anchor Investor Reserveration
Market Maker Reserveration
QIB 42,42,379 shares 9,31,966 shares
NII 32,32,770 shares 6,98,975 shares
RII 75,43,130 shares 16,30,941 shares
Employee 0 shares 0 shares
Others
Total 1,50,18,279 shares 32,61,882 shares

Bids Received (Subscription)

Glenmark Life Sciences IPO subscribed 44.17x in total, whereas Tatva Chintan Pharma IPO subscribed 180.36x.

  Glenmark Life Sciences IPO Tatva Chintan Pharma IPO
QIB (times) 36.97x 185.23x
NII (times) 122.54x 512.22x
Big NII (times)
Small NII (times)
RII (times) 14.63x 35.35x
Employee (times)
Other (times)
Total (times) 44.17x 180.36x

Comments

Add a public comment...